Navigation Links
Acorda's Ampyra Sustains High Levels of Interest Seven Months After Launch With Favorable Future Share Projections
Date:12/13/2010

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that on most metrics, perceptions of Acorda's Ampyra, the first FDA-approved product for the management of a multiple sclerosis (MS) symptom, have remained consistent or improved since earlier waves, including product awareness, interest, satisfaction, the managed care process and Acorda's patient support program. Compared to early in the launch, patient requests play a less impactful role in Ampyra uptake. With increased familiarity after seven months on the market, neurologists are gaining a clear picture of the discontinuation rates, responder rates and insurance dynamics associated with Ampyra.

The recently released third and final wave of the LaunchTrends®: Ampyra report series finds that about half of the surveyed neurologists had been detailed on Ampyra within the past month.  Those considered high prescribers of the brand recall dialogue related to reimbursement. While market share of Ampyra was not significantly different compared to the prior wave, the respondents report starting significantly more dalfampridine-naive patients on Ampyra compared to earlier waves. More than three-quarters of the surveyed neurologists currently prescribe Ampyra and projected market share increases for the brand are expected to come from both an expanded user base as well as increased use among current prescribers.

LaunchTrends®: Ampyra is a three wave syndicated report series designed to track the uptake of Acorda's Ampyra at one month, four months and seven months following its commercial availability. In the current wave of research, which measures Ampyra's market impact at seven month post-launch, BioTrends surveyed 76 neurologists and conducted qualitative interviews with a subset of 20 of the respondents in November 2010. BioTrends will continue to track the uptake of Ampyra in TreatmentTrends®: Multiple Sclerosis, a report series published quarterly in the U.S. and annually in the EU, which provides a comprehensive view of the current and anticipated future management of MS. BioTrends also recently released ChartTrends®: Multiple Sclerosis, a patient chart audit of over 1,000 MS patients assessing how MS patients are being managed with disease modifying agents as well as agents used in symptomatic conditions.  

About LaunchTrendsLaunchTrends assesses trial and use of new products, obstacles to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Decision Resources, Inc.Sharon Funk

Christopher Comfort404-223-2963

781-993-2597 sfunk@bio-trends.com   ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
2. Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004
3. Tocotrienols Shown to be Effective in Lowering Fat Levels in Blood
4. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
5. People at Intermediate Risk of Heart Disease With Elevated hsCRP Benefit From Statin Therapy Even if Cholesterol Levels are Normal
6. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
7. Single Dose of Proprietary Adult Stem Cells Regenerates Damaged Pancreas and Reduces Blood Glucose Levels in Diabetes
8. New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood
9. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
10. Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):